This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier:
NCT01505699
First received: January 4, 2012
Last updated: May 16, 2017
Last verified: May 2017
January 4, 2012
May 16, 2017
January 6, 2012
February 6, 2012   (Final data collection date for primary outcome measure)
  • Comprehensive view of microRNA expression by cytogenetic subgroup [ Time Frame: 1 year ]
  • MicroRNA expression in relation to clinical outcome [ Time Frame: 1 year ]
  • Differential microRNA expression between normal B-cells and progenitors compared to B-ALL [ Time Frame: 1 year ]
  • Comprehensive view of microRNA expression by cytogenetic subgroup
  • MicroRNA expression in relation to clinical outcome
  • Differential microRNA expression between normal B-cells and progenitors compared to B-ALL
Complete list of historical versions of study NCT01505699 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia
Micro RNA Expression Analysis in B-Lineage Adult Acute Lymphoblastic Leukemia From ALL Trial, E2993, Including Patients With Various Cytogenetic and Molecular Abnormalities

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.

PURPOSE: This research study is studying biomarkers in samples from patients with acute lymphoblastic leukemia enrolled on ECOG-2993 clinical trial.

OBJECTIVES:

  • To identify microRNAs that behave as oncogenes or as tumor suppressor genes in B-lineage acute lymphoblastic leukemia (ALL) in vitro and in vivo.
  • To examine if single microRNA or signatures of microRNA correspond to different clinical outcomes in cytogenetically distinct B-ALL groups.

OUTLINE: RNA from archived samples are analyzed for microRNA expression profile in vitro and in vivo.

Observational
Observational Model: Other
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
Samples from patients enrolled on E2993 who provided samples for research
Leukemia
  • Genetic: RNA analysis
  • Genetic: cytogenetic analysis
  • Genetic: microarray analysis
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
186
February 6, 2012
February 6, 2012   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Samples from patients enrolled on ECOG-2993
  • Samples from patients with recurrent cytogenetic abnormalities other than BCR-ABL, including MLL/AF4, E2A/PBX1, and TEL/AML1

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Sexes Eligible for Study: All
15 Years to 65 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01505699
CDR0000720304
ECOG-E2993T4
Not Provided
Not Provided
Not Provided
Not Provided
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Hans-Guido Wendel, MD Memorial Sloan Kettering Cancer Center
Eastern Cooperative Oncology Group
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP